Decay and damage of therapeutic phage OMKO1 by environmental stressors.
Journal
PloS one
ISSN: 1932-6203
Titre abrégé: PLoS One
Pays: United States
ID NLM: 101285081
Informations de publication
Date de publication:
2022
2022
Historique:
received:
30
07
2021
accepted:
25
01
2022
entrez:
23
2
2022
pubmed:
24
2
2022
medline:
9
3
2022
Statut:
epublish
Résumé
Antibiotic resistant bacterial pathogens are increasingly prevalent, driving the need for alternative approaches to chemical antibiotics when treating infections. One such approach is bacteriophage therapy: the use of bacteria-specific viruses that lyse (kill) their host cells. Just as the effect of environmental conditions (e.g. elevated temperature) on antibiotic efficacy is well-studied, the effect of environmental stressors on the potency of phage therapy candidates demands examination. Therapeutic phage OMKO1 infects and kills the opportunistic human pathogen Pseudomonas aeruginosa. Here, we used phage OMKO1 as a model to test how environmental stressors can lead to damage and decay of virus particles. We assessed the effects of elevated temperatures, saline concentrations, and urea concentrations. We observed that OMKO1 particles were highly tolerant to different saline concentrations, but decayed more rapidly at elevated temperatures and under high concentrations of urea. Additionally, we found that exposure to elevated temperature reduced the ability of surviving phage particles to suppress the growth of P. aeruginosa, suggesting a temperature-induced damage. Our findings demonstrate that OMKO1 is highly tolerant to a range of conditions that could be experienced inside and outside the human body, while also showing the need for careful characterization of therapeutic phages to ensure that environmental exposure does not compromise their expected potency, dosing, and pharmacokinetics.
Identifiants
pubmed: 35196336
doi: 10.1371/journal.pone.0263887
pii: PONE-D-21-21818
pmc: PMC8865689
doi:
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
e0263887Déclaration de conflit d'intérêts
Paul E. Turner discloses a financial interest in Felix Biotechnology, Inc., a phage therapeutic company with first rights to use patents resulting from this work. Paul Turner sits on the Board of Directors of Nextbiotics. This does not alter our adherence to PLOS ONE policies on sharing data and materials.
Références
Curr Opin Infect Dis. 2003 Apr;16(2):135-43
pubmed: 12734446
J Microbiol Methods. 2012 Jan;88(1):117-21
pubmed: 22101310
Evol Med Public Health. 2018 Mar 08;2018(1):60-66
pubmed: 29588855
PLoS One. 2012;7(12):e49300
pubmed: 23284623
Appl Microbiol. 1957 May;5(3):152-4
pubmed: 13435725
Antimicrob Agents Chemother. 2003 Jan;47(1):317-23
pubmed: 12499208
Sci Rep. 2016 May 26;6:26717
pubmed: 27225966
Science. 2018 Mar 30;359(6383):1542-1545
pubmed: 29599247
Lancet Infect Dis. 2018 Mar;18(3):318-327
pubmed: 29276051
Bone Joint Res. 2017 May;6(5):296-306
pubmed: 28515059
Biophys J. 1971 Jan;11(1):66-74
pubmed: 5539000
PLoS Pathog. 2015 Jun 11;11(6):e1004847
pubmed: 26066799
Curr Opin Virol. 2014 Oct;8:79-84
pubmed: 25087040
Nature. 2003 Nov 20;426(6964):306-10
pubmed: 14628055
Science. 1956 May 18;123(3203):891-2
pubmed: 13324109
PLoS Med. 2011 Oct;8(10):e1001104
pubmed: 22022233
Analyst. 2012 Feb 7;137(3):595-600
pubmed: 22179722
Pharmacotherapy. 2003 Jul;23(7):916-24
pubmed: 12885104
Microb Ecol. 2011 Oct;62(3):505-17
pubmed: 21503776
Cell Host Microbe. 2019 Feb 13;25(2):219-232
pubmed: 30763536
Appl Microbiol. 1971 Sep;22(3):463-8
pubmed: 4107517
Evolution. 2021 Jul;75(7):1878-1888
pubmed: 33969482
J Bacteriol. 1964 May;87(5):1162-70
pubmed: 5874538
J Mol Biol. 2002 Aug 9;321(2):285-96
pubmed: 12144785
J Infect Public Health. 2009;2(3):101-11
pubmed: 20701869
Front Public Health. 2014 Sep 16;2:145
pubmed: 25279369
FEMS Microbiol Ecol. 2007 Apr;60(1):1-13
pubmed: 17250749
Cold Spring Harb Symp Quant Biol. 1953;18:273-9
pubmed: 13168995
Folia Microbiol (Praha). 2011 May;56(3):191-200
pubmed: 21625877
Virology. 1968 Nov;36(3):343-55
pubmed: 5722182
J Glob Antimicrob Resist. 2013 Jun;1(2):63-69
pubmed: 27873580
Rev Environ Contam Toxicol. 2009;201:71-115
pubmed: 19484589
J Res Med Sci. 2012 Apr;17(4):332-7
pubmed: 23267393
J Chromatogr A. 2015 Oct 9;1415:73-82
pubmed: 26362805
Proc Natl Acad Sci U S A. 2014 Feb 11;111(6):2223-8
pubmed: 24469821
BMJ. 2006 Mar 25;332(7543):702-5
pubmed: 16565125
Evol Med Public Health. 2020 Jul 11;2020(1):148-157
pubmed: 34254028